Related Experiment Video

Updated: May 18, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

Hypercalcemia as a side effect of potassium binding agents

David Arroyo1, Nayara Panizo, Soledad García de Vinuesa

  • 1Servicio de Nefrología, Hospital Universitari Doctor Josep Trueta, Girona, Spain. dvdrry@gmail.com

Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia
|September 28, 2012
PubMed

Insights

Calcium-containing resins used for hyperkalemia in chronic kidney disease (CKD) can cause mild hypercalcemia. Monitoring calcium levels is crucial for CKD patients on these medications to prevent adverse effects.

Area of Science:

  • Nephrology
  • Endocrinology
  • Clinical Pharmacology

Background:

  • Hypercalcemia is a known risk associated with calcium-containing ion exchange resins.
  • These resins are frequently prescribed for managing hyperkalemia in patients with chronic kidney disease (CKD).

Purpose of the Study:

  • To investigate the occurrence and characteristics of mild hypercalcemia in outpatients with moderate CKD treated with calcium polystyrene sulfonate.
  • To assess the impact of calcium polystyrene sulfonate on serum calcium and intact parathormone (iPTH) levels in this patient group.

Main Methods:

  • Retrospective case series of seven outpatients with moderate CKD.
  • Monitoring of serum calcium and iPTH levels before and after treatment adjustment (withdrawal or dose reduction) of calcium polystyrene sulfonate.

Main Results:

  • Seven outpatients with moderate CKD (eGFR 41.29 ± 10.83 mL/min/1.73 m(2)) developed mild hypercalcemia during treatment with calcium polystyrene sulfonate.
  • Mean serum calcium increased by 0.91 ± 0.46 mg/dL, accompanied by a mean iPTH decrease of 52.24 ± 49.29 ng/dL.
  • Serum calcium and iPTH levels normalized after discontinuing or reducing the dose of the resin.

Conclusions:

  • Calcium polystyrene sulfonate can induce mild hypercalcemia in patients with moderate CKD.
  • Calcium-containing potassium binders should be considered in the differential diagnosis of hypercalcemia in CKD patients.
  • Monitoring serum calcium is essential for patients with CKD receiving calcium-based potassium binders.

More Related Videos

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Skeleton and Calcium Homeostasis01:21

Skeleton and Calcium Homeostasis

Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...